Market Overview

Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer


Progression free survival of patients treated with Tumor Treating
Fields plus weekly paclitaxel was more than double that of weekly
paclitaxel-treated historical controls

Novocure (NASDAQ:NVCR) announced today that the results of its INNOVATE
phase 2 pilot trial have been published in Gynecologic
. The INNOVATE trial was a prospective, single-arm study
testing the feasibility, safety and preliminary efficacy of Tumor
Treating Fields combined with weekly paclitaxel in recurrent ovarian
cancer. Tumor Treating Fields is a cancer therapy that uses electric
fields tuned to specific frequencies to disrupt cell division,
inhibiting tumor growth and causing affected cancer cells to die.
Progression free survival of recurrent ovarian cancer patients treated
with Tumor Treating Fields plus weekly paclitaxel was more than double
that of weekly paclitaxel-treated historical controls.

"A clear unmet need remains for patients with recurrent ovarian cancer,
particularly for those patients resistant to platinum-based
chemotherapy, with median overall survival of about 13 months post
recurrence," said Dr. Ignace Vergote, Chairman of the Department of
Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic
University of Leuven, European Union, and an investigator in the trial.
"These phase 2 pilot data show that Tumor Treating Fields combined with
paclitaxel has the potential to increase survival without significantly
increasing side effects for recurrent ovarian cancer patients."

Median progression free survival in the Tumor Treating Fields-treated
group (n=31) was 8.9 months (compared to 3.9 months in paclitaxel-alone
historical controls) and median overall survival was not yet reached.
Median one-year survival in the Tumor Treating Fields-treated group was
61 percent. The median compliance of patients with Tumor Treating Fields
in the first three months of treatment was 77 percent. Two cases of
severe skin irritation due to Tumor Treating Fields were reported. No
other serious device-related adverse events were reported.

"These are encouraging results in a disease state that is very difficult
to treat," said Dr. Eilon Kirson, Novocure's Chief Science Officer and
Head of Research and Development. "We are now working to open
INNOVATE-3, a phase 3 pivotal trial to further study Tumor Treating
Fields for the treatment of recurrent ovarian cancer."

About Ovarian Cancer

In the United States, ovarian cancer ranks fifth in cancer deaths among
women, accounting for more deaths than any other cancer of the female
reproductive system. Ovarian cancer incidence increases with age, and
the median age at time of diagnosis is 63 years old. The incidence of
ovarian cancer is approximately 22,000 new cases annually in the United
States, approximately 68,000 new cases annually in Europe, and
approximately 10,000 new cases annually in Japan. Tumor Treating Fields
is not approved for the treatment of ovarian cancer by the U.S. Food and
Drug Administration. The safety and effectiveness of Tumor Treating
Fields for ovarian cancer has not been established.

About Novocure

Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure's commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit
or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure's current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage, collections
from third-party payers and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.

View Comments and Join the Discussion!